Radiography
Volume 13 , Pages e45-e53 , December 2007

Dynamic contrast-enhanced MR imaging in cancer

Received 21 August 2006 ,Accepted 4 October 2006.

References 

  1. Office of National Statistics . Cancer statistics registrations. London: HMSO; 2005;
  2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108
  3. Royal College of Radiologists . Recommendations for cross-sectional imaging in cancer management. London: The Royal College of Radiologists; 2006;
  4. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–216
  5. Kono K, Inoue Y, Nakayama K, Shakudo M, Morino M, Ohata K, et al. The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol. 2001;22(6):1081–1088
  6. Griffiths JR, Taylor NJ, Howe FA, Saunders MI, Robinson SP, Hoskin PJ, et al. The response of human tumors to carbogen breathing, monitored by gradient-recalled echo magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 1997;39(3):697–701
  7. Abramovitch R, Frenkiel D, Neeman M. Analysis of subcutaneous angiogenesis by gradient echo magnetic resonance imaging. Magn Reson Med. 1998;39(5):813–824
  8. Bruhn H, Frahm J, Gyngell ML, Merboldt KD, Hanicke W, Sauter R, et al. Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. Radiology. 1989;172(2):541–548
  9. Preul MC, Caramanos Z, Villemure JG, Shenouda G, LeBlanc R, Langleben A, et al. Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery. 2000;46(2):306–318
  10. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186
  11. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–257
  12. Fidler IJ. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst. 2001;93(14):1040–1041
  13. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998;394(6692):485–490
  14. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676
  15. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003;9(6):677–684
  16. Gerhardt H, Betsholtz C. Endothelial–pericyte interactions in angiogenesis. Cell Tissue Res. 2003;314(1):15–23
  17. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Yung S, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell. 2006;124(1):175–189
  18. Parker GJM, Padhani AR. T1-weighted dynamic contrast-enhanced MRI. In:  Tofts PS editors. Quantitative MRI of the brain. Wiley; 2003;p. 341–364
  19. Gadian DG. NMR and its applications to living systems. Oxford, New York: Oxford University Press; 1995;
  20. Jackson A, Stivaros S, Moore EA. Advances in magnetic resonance imaging. Imaging. 2006;18(2):97–109
  21. Graham RN, Perriss RW, Scarsbrook AF. DICOM demystified: a review of digital file formats and their use in radiological practice. Clin Radiol. 2005;60(11):1133–1140
  22. Buonaccorsi GA, Roberts C, Cheung S, Watson Y, O'Connor JP, Davies K, et al. Comparison of the performance of tracer kinetic model-driven registration for dynamic contrast enhanced MRI using different models of contrast enhancement. Acad Radiol. 2006;13(9):1112–1123
  23. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer. 2005;92(9):1599–1610
  24. Parker GJM, Buckley DL. Tracer kinetic modelling for T1-weighted DCE-MRI. In:  Jackson A,  Buckley DL,  Parker GJM editor. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Berlin: Springer; 2005;p. 81–92
  25. Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology. 1994;191(1):41–51
  26. Fisel CR, Ackerman JL, Buxton RB, Garrido L, Belliveau JW, Rosen BR, et al. MR contrast due to microscopically heterogeneous magnetic susceptibility: numerical simulations and applications to cerebral physiology. Magn Reson Med. 1991;17(2):336–347
  27. Jackson A. Imaging microvascular structure with contrast enhanced MRI. Br J Radiol. 2003;76:S159–S173
  28. Kassner A, Annesley DJ, Zhu XP, Li KL, Kamaly-Asl ID, Watson Y, et al. Abnormalities of the contrast re-circulation phase in cerebral tumors demonstrated using dynamic susceptibility contrast-enhanced imaging: a possible marker of vascular tortuosity. J Magn Reson Imaging. 2000;11(2):103–113
  29. Calamante F, Thomas DL, Pell GS, Wiersma J, Turner R. Measuring cerebral blood flow using magnetic resonance imaging techniques. J Cereb Blood Flow Metab. 1999;19(7):701–735
  30. Li KL, Zhu XP, Waterton J, Jackson A. Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors. J Magn Reson Imaging. 2000;12(2):347–357
  31. van Gelderen P, Grandin C, Petrella JR, Moonen CT. Rapid three-dimensional MR imaging method for tracking a bolus of contrast agent through the brain. Radiology. 2000;216(2):603–608
  32. Sugahara T, Korogi Y, Kochi M, Ushio Y, Takahashi M. Perfusion-sensitive MR imaging of gliomas: comparison between gradient-echo and spin-echo echo-planar imaging techniques. AJNR Am J Neuroradiol. 2001;22(7):1306–1315
  33. Donahue KM, Krouwer HG, Rand SD, Pathak AP, Marszalkowski CS, Censky SC, et al. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med. 2000;43(6):845–853
  34. Jackson A. Analysis of dynamic contrast enhanced MRI. Br J Radiol. 2004;77:S154–S166
  35. Calamante F. Quantification of dynamic susceptibility contrast T2∗ MRI in oncology. In:  Jackson A,  Buckley DL,  Parker GJM editor. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Berlin: Springer-Verlag; 2005;p. 53–67
  36. Aronen HJ, Pardo FS, Kennedy DN, Belliveau JW, Packard SD, Hsu DW, et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res. 2000;6(6):2189–2200
  37. Knopp EA, Cha S, Johnson G, Mazumdar A, Golfinos JG, Zagzag D, et al. Glial neoplasms: dynamic contrast-enhanced T2∗-weighted MR imaging. Radiology. 1999;211(3):791–798
  38. Law M, Oh S, Johnson G, Babb JS, Zagzag D, Golfinos J, et al. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery. 2006;58(6):1099–1107
  39. Lupo JM, Cha S, Chang SM, Nelson SJ. Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. AJNR Am J Neuroradiol. 2005;26(6):1446–1454
  40. Ostergaard L, Hochberg FH, Rabinov JD, Sorensen AG, Lev M, Kim L, et al. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood–brain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg. 1999;90(2):300–305
  41. Kvistad KA, Lundgren S, Fjosne HE, Smenes E, Smethurst HB, Haraldseth O. Differentiating benign and malignant breast lesions with T2∗-weighted first pass perfusion imaging. Acta Radiol. 1999;40(1):45–51
  42. Padhani AR, Ah-See M-LW, Taylor NJ, Stirling JJ, Daley FM, Richman PI, et al. MRI correlates of tumour grade and hypoxia status in human breast cancer. Proc Intl Soc Mag Res Med. 2005;13:90
  43. Ah-See M-LW, Makris A, Taylor NJ, Burcombe RJ, Harrison M, Stirling JJ, et al. Does vascular imaging with MRI predict response to neoadjuvant chemotherapy in primary breast cancer?. J Clin Oncol. 2004;22(14S):582;[Meetings Abstracts]
  44. Roberts C, Issa B, Stone A, Jackson A, Waterton JC, Parker GJ. Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. J Magn Reson Imaging. 2006;23(4):554–563
  45. Henderson E, Rutt BK, Lee TY. Temporal sampling requirements for the tracer kinetics modeling of breast disease. Magn Reson Imaging. 1998;16(9):1057–1073
  46. Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR. 1984;16(2):167–172
  47. Fritz-Hansen T, Rostrup E, Larsson HB, Sondergaard L, Ring P, Henriksen O. Measurement of the arterial concentration of Gd-DTPA using MRI: a step toward quantitative perfusion imaging. Magn Reson Med. 1996;36(2):225–231
  48. Haase A. Snapshot FLASH MRI. Applications to T1, T2, and chemical-shift imaging. Magn Reson Med. 1990;13(1):77–89
  49. Bluml S, Schad LR, Stepanow B, Lorenz WJ. Spin–lattice relaxation time measurement by means of a TurboFLASH technique. Magn Reson Med. 1993;30(3):289–295
  50. Daniel BL, Yen YF, Glover GH, Ikeda DM, Birdwell RL, Sawyer-Glover AM, et al. Breast disease: dynamic spiral MR imaging. Radiology. 1998;209(2):499–509
  51. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002;62(12):3408–3416
  52. Miles KA. Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Eur J Radiol. 1999;30(3):198–205
  53. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging. 1999;10(3):254–259
  54. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10(3):223–232
  55. Tofts PS, Kermode AG. Measurement of the blood–brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med. 1991;17(2):357–367
  56. Larsson HB, Stubgaard M, Frederiksen JL, Jensen M, Henriksen O, Paulson OB. Quantitation of blood–brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med. 1990;16(1):117–131
  57. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging. 1997;7(1):91–101
  58. St Lawrence KS, Lee TY. An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: I. Theoretical derivation. J Cereb Blood Flow Metab. 1998;18(12):1365–1377
  59. Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?. Radiology. 1999;211(1):101–110
  60. Gribbestad IS, Nilsen G, Fjosne HE, Kvinnsland S, Haugen OA, Rinck PA. Comparative signal intensity measurements in dynamic gadolinium-enhanced MR mammography. J Magn Reson Imaging. 1994;4(3):477–480
  61. Barentsz JO, Jager GJ, van Vierzen PB, Witjes JA, Strijk SP, Peters H, et al. Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. Radiology. 1996;201(1):185–193
  62. Mayr NA, Yuh WT, Magnotta VA, Ehrhardt JC, Wheeler JA, Sorosky JI, et al. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int J Radiat Oncol Biol Phys. 1996;36(3):623–633
  63. Martincich L, Montemurro F, De Rosa G, Marra V, Ponzone R, Cirillo S, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat. 2004;83(1):67–76
  64. Cao Y. Antiangiogenic cancer therapy. Semin Cancer Biol. 2004;14(2):139–145
  65. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol. 2002;20(18):3906–3927
  66. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev. 2005;15(1):102–111
  67. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–2342
  68. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184–2191
  69. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23(4):792–799
  70. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427–434
  71. Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, et al. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst. 2006;98(9):580–598
  72. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol. 2003;21(21):3955–3964
  73. Mross K, Drevs J, Muller M, Medinger M, Marme D, Hennig J, et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer. 2005;41(9):1291–1299
  74. Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol. 2005;23(18):4162–4171
  75. O'Dwyer PJ, Rosen M, Gallagher M, Schwartz B, Flaherty KT. Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23(16S):3005;[Meetings Abstracts]

PII: S1078-8174(06)00118-0

doi: 10.1016/j.radi.2006.10.001

Radiography
Volume 13 , Pages e45-e53 , December 2007

Article Tools

* Image Usage & Resolution